CLL Microlearning Series – Video #6: Zanubrutinib’s Cardiovascular Profile
Zanubrutinib’s Cardiovascular Profile
Cardiovascular safety is a key consideration when selecting a BTK inhibitor for CLL patients, many of whom are older and may already have cardiac comorbidities.
In this video, an APP specializing in CLL explains how zanubrutinib compares to other BTK inhibitors and outlines practical steps clinicians can take to evaluate and manage cardiovascular risk.
In This Video, You’ll Learn:
- Why BTK inhibitor–related arrhythmias—especially atrial fibrillation—are a key safety concern
- Comparative rates of atrial fibrillation across BTK inhibitors (ibrutinib 16%, acalabrutinib 9%, zanubrutinib 4%)
- How zanubrutinib’s lower arrhythmia rates support safer use in older adults or those with pre-existing cardiac disease
- How to assess whether a patient’s cardiovascular condition is stable enough for BTK inhibitor therapy
- Medication interactions to review, including anticoagulants and rate-controlling drugs
- Best practices for baseline cardiovascular evaluation, including pre-treatment EKG and cardiology involvement when appropriate
More from this series
CLL Microlearning: Setting the Stage for Treatment Decisions in CLL
This segment outlines the key patient and disease characteristics that inform when—and how—to approach therapy in a thoughtful, individualized way.
January 12, 2026
CLL Microlearning: Considerations for 1st Line Therapy
This short module highlights the practical, real-world cues that signal true disease progression—ensuring therapy begins at the appropriate time and for the right reasons. An APP specializing in CLL walks through how to interpret clinical symptoms, lab trends, and iwCLL criteria in everyday practice.
November 13, 2025
CLL Microlearning: Why Zanubrutinib is a Meaningful Option
This segment highlights why zanubrutinib has emerged as a meaningful choice in frontline and relapsed CLL, especially for older adults and those with cardiovascular comorbidities who may be more vulnerable to off-target toxicities.
November 13, 2025
CLL Microlearning: Practical Aspects of Prescribing Zanubrutinib
This video covers the key practical details clinicians should know when prescribing zanubrutinib. As a second-generation BTK inhibitor, it offers effective disease control with a flexible dosing schedule that can be tailored to patient needs.
November 13, 2025
CLL Microlearning: Zanubrutinib’s Cardiovascular Profile
In this video, an APP specializing in CLL explains how zanubrutinib compares to other BTK inhibitors and outlines practical steps clinicians can take to evaluate and manage cardiovascular risk.
November 13, 2025
CLL Microlearning: Empowering Patients Through Choice and Communication
This video outlines how APPs can use communication and side-effect counseling to support consistent, long-term adherence to zanubrutinib.
November 13, 2025
CLL Microlearning: Personal Insights and Practice-Based Learning
In this video, an APP specializing in CLL reflects on how newer options—particularly zanubrutinib—support more individualized care by balancing efficacy, safety, and patient preferences.
November 13, 2025